Race Oncology Reaches Critical Trial Milestone with RC220 Cancer Drug

May 02, 2025 11:10 AM AEST | By Team Kalkine Media

Google News:

Race Oncology Reaches Critical Trial Milestone with RC220 Cancer Drug — Image source: shutterstock

Recent News

Boeing Commercial Airplanes head meets Air India chairman after fatal...

Bravery Over Bladder: Former Marine Tackles Taboo Topic

Forward Air stock surges on report PE firms express acquisition intere...

RBC initiates Knife River, Martin Marietta amid continued infrastructu...

Highlights

First patient dosed in Phase 1 RC220 trial

Breakthrough formulation eliminates prior safety concern

Global trial expansion planned in 2025

Race Oncology (ASX:RAC) has marked a significant milestone with the successful dosing of the first patient in its Phase 1 clinical trial for RC220, a next-generation cancer drug aimed at advanced solid tumours. The development represents a major step forward in the company's years-long effort to reformulate a previously promising compound that faced hurdles in clinical application due to safety concerns.

At the heart of this breakthrough is a redesigned version of the drug that overcomes phlebitis—a painful and potentially harmful inflammation of the veins—that previously limited its use. With this critical issue resolved, RC220 now enters human testing with improved safety parameters and a renewed potential for therapeutic success.

The Phase 1 trial is currently underway in Australia and is expected to expand to Hong Kong and South Korea later this year. The trial aims to enrol up to 33 patients for initial dose determination, followed by an additional cohort of up to 20 patients in a dose expansion phase. The trial’s goal is not only to assess safety and tolerability but also to evaluate RC220’s dual function: its ability to fight cancer while offering cardioprotective benefits.

Preclinical studies have shown that RC220 may help safeguard the heart when used alongside doxorubicin, a widely used chemotherapy drug known for its cardiotoxic effects. This cardioprotective aspect could make RC220 a unique player in oncology treatment, especially in cases where heart damage limits the effectiveness of traditional chemotherapy.

Adding to its credibility, RC220 has a long history of use in over 50 previous clinical trials, giving it a relatively de-risked profile as it moves through the current development pipeline. This background could provide confidence to market participants who follow biotech developments, especially within broader ASX200 trends.

While Race Oncology is a clinical-stage biotechnology company and not traditionally grouped under ASX dividend stocks, the successful advancement of RC220 may draw wider attention from investors monitoring healthcare innovations and long-term potential plays.

With plans to broaden the clinical trial’s reach and a formulation that addresses long-standing challenges, RC220 could become a meaningful development in the treatment landscape for advanced solid tumours.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.